<SEC-DOCUMENT>0001104659-25-105594.txt : 20251103
<SEC-HEADER>0001104659-25-105594.hdr.sgml : 20251103
<ACCEPTANCE-DATETIME>20251103164401
ACCESSION NUMBER:		0001104659-25-105594
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251103
DATE AS OF CHANGE:		20251103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		251444821

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20251103x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.1.0.0 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/3/2025 9:37:11 AM -->
<!-- iXBRL Library version: 1.0.9397.4506 -->
<!-- iXBRL Service Job ID: f0148243-5f3f-4e57-a56e-9be16537d8fe -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20251103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>Protalix BioTherapeutics,&#160;Inc._November&#160;3, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityCentralIndexKey" id="Tc_de-KN9oQA0CK6xEAmT-suw_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:AmendmentFlag" id="Tc_Ue2kbsW0GUG90t2I3p1rEQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20251103.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-03</xbrli:startDate><xbrli:endDate>2025-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_64151476_db81_4283_b96d_10a1c841f313"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:DocumentType" id="Narr_ntgS5ZV3m02PzYkrFhbE9w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_yMZLJ3hXNUS_4aEfeHp03Q"><b style="font-weight:bold;">November&#160;3, 2025</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityRegistrantName" id="Narr_AIoaWmmyIkq2HIQVRreFSw"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_So9QRey9ikCdjxocZRHjeg_2_0"></a><a id="Tc_gKZ8tHo_W0S1tizhG-UuFA_2_2"></a><a id="Tc_Miw9Zat2yEW16uGMMW94NQ_2_4"></a><a id="Tc_S9tvVzQuHEa8l-TMjx0Obw_6_0"></a><a id="Tc_x-9IuWNF4E26xYjUb897EQ_7_0"></a><a id="Tc__UM8Lm-Sn0ipO03swsA1Fg_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_HoNlW5W6XUOTern_pLxp0w_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityFileNumber" id="Tc_mU-GmT1W5Ea4GOB3j5FWpQ_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityTaxIdentificationNumber" id="Tc_xvgG2koBAU62yP3bf5y_Fw_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br/><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityAddressAddressLine1" id="Tc_WjxqoVnOlEO9xDhahRMrrA_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityAddressAddressLine2" id="Tc_xcznGRV9H0uPPFT2fy9t-Q_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityAddressCityOrTown" id="Narr_BrRBU2W5akeJfje23bucDw"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityAddressStateOrProvince" id="Narr_3nu3YpvD4EqK5JJy-vj86w"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:EntityAddressPostalZipCode" id="Tc_yGhUkSrnN0OB1jQElg5zyw_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:CityAreaCode" id="Narr_JitYTEvMZkW1_SN9XRHpMg"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:LocalPhoneNumber" id="Narr_2c1RZRVjgEe-Pw2eXxzsVg"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_yWq3PfyWOkW0I1kS9wwLXg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_Huli07RVo0mEEpcKgXLEOQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_F8uOByrEb0KH7M6IS_fZlA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_XVlNtihHW0mbCtGN7P7SSA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_8gLmBYr7IkCLyAER2EO5OQ_1_0"></a><a id="Tc_SD8KnVKx-EaBYtYjI4ZBzw_1_1"></a><a id="Tc_RbRnRT84jU6cdQ1_WtBYjQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:Security12bTitle" id="Tc_Coaiyv1vik2yxlwmcjTYrQ_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" name="dei:TradingSymbol" id="Tc_vN4mfBnLDkWPhiBknzVT0g_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_4IAXicxuMUCMajibyrunYA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_dJm_ERjlZEu5ngMHiLQkZg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Item&#160;8.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Other Events</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">On November&#160;3, 2025, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that they have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio</span><sup style="color:#212529;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">&#174;</sup><span style="color:#212529;background:#ffffff;"> (pegunigalsidase alfa). A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span>Financial Statements and Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20251103xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated November&#160;3, 2025</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;3, 2025</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and<br/>Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20251103xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/3/2025 09:37:10 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:9.56%;padding-right:9.56%;position:relative;"><div style="margin-top:30pt;min-height:35.25pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.06%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><img src="plx-20251103xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:48.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:128.65pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:right;margin:0pt;"><img src="plx-20251103xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:48.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:134.75pt;"></p></td></tr></table></div><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Chiesi Global Rare Diseases and </b><b style="font-size:12pt;font-weight:bold;">Protalix BioTherapeutics Seek Re-examination from the </b><b style="font-size:12pt;font-weight:bold;">EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU</b><b style="font-size:12pt;font-weight:bold;"> </b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PARMA, Italy and CARMIEL, Israel&#160;&#8211; Nov. 3,</b><b style="color:#242424;font-size:12pt;font-weight:bold;"> </b><b style="font-size:12pt;font-weight:bold;">2025 &#8211; </b><font style="font-size:12pt;">Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2&#160;mg/kg body weight infused every 4 weeks (E4W) for Elfabrio</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> (pegunigalsidase alfa).</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">The opinion concerns the request to add the E4W dosing regimen to the currently approved 1&#160;mg/kg every 2 weeks (E2W) regimen. The existing marketing authorization for Elfabrio remains in effect pending the outcome of the re-examination procedure and subsequent decision by the European Commission (EC).</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Both Chiesi and Protalix remain </font><font style="font-size:12pt;">fully committed to working closely with the EMA through the re-examination process and to addressing the high unmet medical needs of the Fabry community. </font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Important Safety Information</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Indication</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Elfabrio</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> (pegunigalsidase alfa-iwxj) is indicated for the treatment of adults with confirmed Fabry disease.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Important Safety Information</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Elfabrio administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue Elfabrio immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Elfabrio may be considered.</font></p></td></tr></table></div><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.56%;margin-right:9.56%;margin-top:30pt;page-break-after:always;width:80.88%;border-width:0;"><div style="max-width:100%;padding-left:9.56%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">symptoms of hypersensitivity reactions and infusion-associated reactions (IARs), and instruct them to seek medical care immediately if such symptoms occur.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Verdana Pro Light';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Verdana Pro Light';font-size:12pt;font-style:normal;font-weight:normal;">If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Elfabrio administration and initiate appropriate medical treatment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Verdana Pro Light';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Verdana Pro Light';font-size:12pt;font-style:normal;font-weight:normal;">If a mild to moderate hypersensitivity reaction or IAR occurs, consider slowing the infusion rate or temporarily withholding the dose.</font></td></tr></table><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">In clinical trials, 20 (14%) Elfabrio-treated patients experienced hypersensitivity reactions. Four Elfabrio-treated patients (3%) experienced anaphylaxis reactions that occurred within 5 to 40 minutes of the start of the initial infusion. The signs and symptoms of hypersensitivity reactions and anaphylaxis included headache, nausea, vomiting, throat tightness, facial and oral edema, truncal rash, tachycardia, hypotension, rigors, urticaria, intense pruritus, moderate upper airway obstructions, macroglossia, and mild lip edema.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">In clinical trials, 41 (29%) Elfabrio-treated patients experienced one or more infusion-associated reactions, including hypersensitivity, nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If glomerulonephritis is suspected, discontinue treatment until a diagnostic evaluation can be conducted.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">When switching to Elfabrio from a prior enzyme replacement therapy, the risk of hypersensitivity reactions and infusion-associated reactions may be increased in certain patients with pre-existing anti-drug antibodies (ADAs). Consider monitoring IgG and IgE ADAs and clinical or pharmacodynamic response (eg, plasma lyso-Gb3 levels). The most common adverse reactions (</font><font style="font-size:12pt;">&#8805;</font><font style="font-size:12pt;">15%) were infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Please see</font><font style="color:#b90066;font-size:12pt;text-decoration-line:none;"> </font><font style="font-size:12pt;">Full Prescribing Information</font><font style="color:#b90066;font-size:12pt;text-decoration-line:none;"> </font><font style="font-size:12pt;">for Elfabrio.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Fabry disease is a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene, which leads to a deficiency of the enzyme alpha-galactosidase A. This deficiency results in an accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body&#8217;s cells, affecting the heart, kidneys, skin, nervous system, and other organs. Fabry disease can cause a range of serious signs and symptoms, including fatigue, chronic pain, gastrointestinal issues, decreased ability to sweat, progressive kidney failure, heart complications, and increased risk of stroke.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.56%;margin-right:9.56%;margin-top:30pt;page-break-after:always;width:80.88%;border-width:0;"><div style="max-width:100%;padding-left:9.56%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">The condition affects both males and females and can present from childhood through adulthood, often with delayed diagnosis or misdiagnosis. While Fabry disease is rare, early detection and access to appropriate treatment &#8212; such as enzyme replacement therapy or pharmacological chaperones &#8212; are critical in managing symptoms and slowing disease progression.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="font-family:'Verdana Pro Light';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company&#8217;s mission is to improve people&#8217;s quality of life and act responsibly towards both the community and the environment.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi&#8217;s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group&#8217;s research and development center in Parma works alongside 6 other important R&amp;D hubs in France, the US, Canada, China, the UK, and Sweden.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">For more information visit&#160;</font><font style="font-size:12pt;">www.chiesi.com</font><font style="color:#0e2740;font-size:12pt;">.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="color:#0e2740;font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Chiesi Global Rare Diseases</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt;"><font style="color:#0e2740;font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;padding-bottom:3pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">For more information visit&#160;</font><font style="font-size:12pt;">www.chiesirarediseases.com</font><font style="color:#0e2740;font-size:12pt;">.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;padding-bottom:3pt;background:#ffffff;margin:0pt;"><font style="color:#0e2740;font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;background:#ffffff;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Follow @ChiesiGlobalRareDiseases on&#160;</font><font style="font-size:12pt;">LinkedIn</font><font style="color:#0e2740;font-size:12pt;">,&#160;</font><font style="font-size:12pt;">Facebook</font><font style="color:#0e2740;font-size:12pt;">,&#160;</font><font style="font-size:12pt;">Instagram</font><font style="color:#0e2740;font-size:12pt;">,&#160;</font><font style="font-size:12pt;">X</font><font style="color:#0e2740;font-size:12pt;">&#160;</font><font style="font-size:12pt;">and</font><font style="color:#0e2740;font-size:12pt;">&#160;</font><font style="font-size:12pt;">YouTube</font><font style="color:#0e2740;font-size:12pt;">.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.56%;margin-right:9.56%;margin-top:30pt;page-break-after:always;width:80.88%;border-width:0;"><div style="max-width:100%;padding-left:9.56%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix&#8217;s first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix&#8217;s second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX&#8211;115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX&#8211;119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Protalix BioTherapeutics, Inc. Forward-Looking Statements</b></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the commercialization of Elfabrio; risks relating to Elfabrio market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; the possible disruption of Protalix&#39;s operations due to the war declared by Israel&#39;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of Protalix&#39;s suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict; delays in the approval or potential rejection of any applications filed with the FDA, EMA or other health regulatory authorities for Protalix&#39;s product candidates, and other risks relating to the review process; the risk that the results of clinical trials will not support the applicable claims of safety or efficacy; risks related to the amount and sufficiency of Protalix&#8217;s cash and cash equivalents; risks relating to changes to published interim, topline or preliminary data from clinical trials; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; and risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.56%;margin-right:9.56%;margin-top:30pt;page-break-after:always;width:80.88%;border-width:0;"><div style="max-width:100%;padding-left:9.56%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and Protalix disclaims any obligation to update this information, except as may be required by law.</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Chiesi Global Rare Diseases Media Contact</b><br><b style="font-size:12pt;font-weight:bold;">Sky Striar</b><br><i style="font-size:12pt;font-style:italic;">LifeSci Communications</i><br><font style="font-size:12pt;">Email:&#160;</font><font style="font-size:12pt;">sstriar@lifescicomms.com</font> </p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Verdana Pro Light';font-size:11pt;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Protalix BioTherapeutics, Inc. Investor Contact</b><font style="font-size:12pt;"><br></font><b style="font-size:12pt;font-weight:bold;">Mike Moyer, Managing Director</b><font style="font-size:12pt;"><br></font><i style="font-size:12pt;font-style:italic;">LifeSci Advisors</i><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">+1-617-308-4306</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Email:&#160;</font><font style="font-size:12pt;">mmoyer@lifesciadvisors.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:9.56%;margin-right:9.56%;margin-top:30pt;page-break-after:avoid;width:80.88%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20251103xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20251103xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B 0(# 2(  A$! Q$!_\0
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MSW\O'H37DQ_X+F'S\CX,?N?0^)_F_/[)_2O/_P#@G/\ \$Z_"W[0O@JX\?\
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M)%C!?'H55J^]A_P5"_9D(S_PLU?_  1ZE_\ (U(Q/IK6=5@T'1[[4KHD6UG
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M'B&SCDV3:W<V^G@ X)7=YC?^@#\Z^P*_,#_@MGXU\CPUX \+))S//-?2(#V
M"C/ZT ?+_P#P2?\ !7_"5_M:Z7>/'YD.CV4]XW'0X"@_^/5[+_P6R\:_;_B%
MX"\+))N33K"6\=,_=>5\?^@HM;/_  1'\#-+JGQ%\7R1_NXDM]-ADQ_$<NX_
M(I7S1_P4_P#&W_"9?M?^+$63S(=+$6GH<]-B#(_,F@#[#_X(F^"OLG@7Q[XK
MD3'VN^CL8Y/:--S#\W%?GU^VKX^;XE?M1?$/6S(9(VU22WB).<1QGRU'X!17
MZ]?\$V? TG@#]A_09WC,=YJT%UJ['&-PD+&(_P#? 2OPS\078U#QMJ%SJ.\+
M-?N]QC[V#(=WX]: /HSP-\&_VN]'\*Z?#X4T;Q_8: \0FM(M/GDBAV/\P95#
M@#.<_C6[_P *P_;=_P"?+XF?^!LO_P 77[;>!_'/A/7/!^C7VA:[I=WI$UI&
MUK-;7*&-H]HQCG]*\K_:^_:V\/?LS?"'4?$46HZ9J/B64"'2-)>X#-=3$C)*
MJ=VQ022?H.XH _%R_P#V(_VC?$.KS7NH_#3Q/=WUY,9)[NZBW,[L>6=B<GDY
M)K]J?C#^S[=^/OV--1^$FCSI9W__  C=MIMDTIVIYL"1F-&(Z*S1!2>< DX-
M?'O[*_\ P4]^*?[17QV\+^!!X/T&"UU&9FO+BW\TO!;HI:1QDXX []R*](_;
M_P#^"AOB7]D_XF:%X3\-:#IFK/=:8-0N9-0+@KND9$"[2/[C9H _*SQ9^RU\
M:OA-K\*:CX \3:?J$$A>"ZL+.68!D;ATDB! YP0<_2NT'[4G[4WPYT5$N?%W
MCG1]-@.T2:E!(%4D]"\J?S-?JA^P%^V[>_M5:#XKN?%K>']!U/2[B*.#3K2X
M*RM$RDM*RNV2N["@CN#[5]67.M^'Y(F^T:AIK1 9;S9HRH]SDT ?@SX2_P""
MG?[1'A2\\X^.#K*'&Z'5;2*9",]/N@CZ@YK]??V+_P!JF/\ :J^"Z^+;C3HM
M)UBRF:UU*TMV)A651NW)G)"D'."21ZFOQW_X*0>,O!/C?]JKQ#>> TTYM)@@
MAM;B[TI5$%W=+DRR@KPQY"EAUV=^M?>/_!/;2I_@M_P3]\9>,]05K5=06]U.
M(MQ^[2+8K#V)4_E0!^8?[4/B]OB)^T;\0-<#^:MYK,XC;KE%;8@_[Y4"OWS_
M &0?!8\ ?LT?#O1RGER)I$,\@QSND7S#GW^:OY[_ (5>&;KXI?&3PSHB9:[U
MO6(83@9^:249_G7]-5C90Z;96]I;H([>WC6*-!_"JC 'Y"@">BBB@ KQ[XT>
M$Q#.FMVZ860B.X '\79OZ?E7L-5=3TV#5[">SND$D$RE&4_YZT ?+FGZE=:3
M=+<V<[V\Z@@21G!&:U_^%@>(_P#H,77_ 'W7>7/P(#3L;?5=D6?E62+)'X@U
M%_PH>;_H+I_WX/\ C038XC_A8'B/_H,77_?=;O@OXE:I:^(+8:E?RW5E*?+D
M65LA<]&Z=JVO^%#S?]!=/^_!_P :/^%#S?\ 073_ +\'_&@-3S[]K3]DK_A?
MFO>&=:T=X;348YDM=0N6_BL\D[NHR5R<#ODU]%^%O#5AX.\.:=H>EQ>1I]A
MMO"G?:HQD^YZGW-.\.:;<:/H]O97-PMU)"NP2JNW*]LBM.M95)2BH-Z(];$9
MGBL3A:6#JRO"G?E7K_ET[!7QC^WI_P $];/]J[[+XE\.:C;Z#XZLHO(\Z[5C
M;WL0Y"2%02I'9@#UY%?9U%9'EGX!^+O^"7_[1/A-XP/!(UE7) ;2;V&?&.Y&
MX8S7-_\ #O7]HG_HE>L_G%_\77]$%% 'X&^"/^"6?[0WC)@9O"4'AZ$2!'DU
MB]CB*@_Q;022!["OTR_8<_X)ZZ)^R?#+KVL7\'B7QY=Q^7)?11%8+-#UCAW<
MG/=R 3Z"OL"B@#X,_P""K/PB^)?QM\(>$/#_ (!\*WWB."&ZDN;PVA0",X 7
M.YA7"?\ !*7]DKQ_\$_&_C+Q'\0/"]UX<EELXK2P%T4+298ER-I/&-M?I=10
M 5^5'_!4+]G#XR?'KX[V%UX/\#:EKGA[3-,BMXKNW,8C>1B7?&6!R"<?A7ZK
MT4 ?)'_!,SX#^(/@%^SJVG>*](ET7Q%J.I3WMW9S8+KT1,X)'**M?F9\7?V(
M_P!HOXF?%GQ3XED^&6K?\3C5)[H2.\6 'D)!^_TP:_>JB@#D?A3X.C\"_"WP
MMX8$6R+2]+M['RB.@2,*1^E?EM^U-_P2+\=7GQ&U;Q!\++C3M8T+5+A[D:9>
M7 MKBS9B69<M\KKD\$$'U'&3^N]% '\\<G_!/+]HN&1D'PNUAL'&Y'B(/T^>
MNF\&?\$N?VA_&,I$G@^/08ED5'DUB]BAP#U8 $E@.^!FOWVHH ^3?V%?V"M'
M_9#T>]U/4+Z'Q%X]U2,17>IQ1E8;:'.?(@#<[20"S'!8@<  "N _X*1_L"^(
M?VH+_1?&7@:ZM/\ A*-,M?L$^G7LGE+=P[RRE)#PK*7<X; (/7. ?O&B@#^>
MK5?^"<G[16DZA/:_\*TU&[,3%?.M)8I(W]U;?R*@B_X)Y?M%32I'_P *NUA-
MQQN=X@!]3OK^ARB@#\>OV=_^"./C/5O$UGJ/Q:O[+0O#UO*'ETK3K@3W=V!@
M[=Z_+&IZ$Y+>@[U]X?MH_#K79?V/O$'@+X7>&I+V\FM;?2K+2M/"J([;>BN!
MD@8$8;ZU]*T4 ?C+^P9^PK\6O!7[3GA/Q'XX\#7VAZ#I+O=-<W1C*^8J'8.&
M)SNQ7[-444 %%%% !115#7M;LO#6B:AJ^I3I:Z?86\ES<3N<+'&BEF8^P )H
M OUD^)?%.F>$+"&]U:Y%I;37=O9(Y4G,T\JQ1+Q_>=U'XUX[X;\<_&/QMX8A
M\;Z5HWAJST6\07FG^&;\S"_N;0C<C/<!O+BE=>0FQE&0"W4CC=4^+MS\;OV?
M=*\376FG26_X6'IEE':.I61(X->@C3S%).'PHW#H#F@#ZJJ.>9+:&260[8XU
M+,?0#DUY!XE^*?BGQ-\4-0\ _#NTTQ;G1;:*YUW7]9#R6UD9<^3;QQ1L&EF9
M59R"R*J[3DEL4OA3XE^(KCQ#XD\ ^.-/LK7Q+::8^I6=_I)<V>I6>=AD57^:
M*169 T9)^^""PS@ ]4T36K/Q%I%IJ>GS"XLKN,2PR@$;E/0X-7J^8?@GXP^)
MOCWX6:-<^!+30-)T#3K,6EO<^)(9WEU2>/Y9-BQLOE1!@R;V#$E20N,$^E^"
M/BEX@^)'P]U2YT?1K"P\;Z9<R:=>:5JETXM8;I,9_>HC,T9!#*0N2" <&@#U
M.L;2/&&DZ]K>LZ18W8GU#1WC2]A"D&(R*609(P<@'I7DU]\2OB/\+_$/AL>/
MK;PWJ7AO6[V+3&U#0!/!)I]S*<1[TE9@\9; W J1G[M3?!K_ )+K\;/^OO3?
M_1$E 'ME%>;_ +0GQ*U7X2?"O5/$NB:9#K.J6S1)!97#E$E9W"X+#IUZUF>&
M9OC;-)I5]JZ^"'M+DA[S3(/M<4MJA&<).=XD8=P40'UH ];HKQ?Q3K'QPT*S
MU36[>Q\$7=C9%YDT6.6[-S/;J"3BX(55D(' \LKGC-<QXH_:1\5Z]?\ PNM/
MAMH&G:B_C>SGNC+K4KQK8+&!N=]F2P4Y!4<DXY% 'T?17BOB+XB^//@YX?U3
M7/'?_".:YI4<<<5DN@QW%M>7%Y(P6. 12%U(9B!NWC R<5G:O\2OBG\-M.TO
MQ/XTT[PY<>&KF>*+4;+21,MUI2R,%1_,=BLP4D!OE3'49H ][HJK=:I:V6ER
MZC/,L=E%"9WF/0(!N+?E7B'A_P"('Q=^)&BR>+_#&D>&],\.2,9-+TC63,U]
MJ-N#Q(\J'9 7 RJ[7QD;L<T >C7'QB\'V>F3ZA<:U#!9PZH-&>5T; NR_EB+
MIU+'&>E=D#D9'2OD3X,_&.\T#X3^(?$]KI)@NM0\>R6,MC?Y#0>==B-P<=2N
M3CL:]5USXB>.O%7Q-USPEX%'AW3DT&WADO;W7UFF>>65=R)'%&RX0#JY)YZ
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MD\6_ [6-7BM)+*&[^)D4L<4J;&VF_7!([9'/XU[C\0?"WPO^*GC#4(D\5?\
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G7;+F&.X3?C;*H8?K7N]M#'! B1(L: <*@P!^%%%)"1+1113&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20251103xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20251103xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20251103.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2025 9:37:14 AM-->
<!--Modified on: 11/3/2025 9:37:14 AM-->
<xsd:schema targetNamespace="http://protalix.com/20251103" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:plx="http://protalix.com/20251103" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20251103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20251103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20251103_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2025 9:37:14 AM-->
<!--Modified on: 11/3/2025 9:37:14 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20251103.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20251103_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2025 9:37:14 AM-->
<!--Modified on: 11/3/2025 9:37:14 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20251103.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20251103.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638977594345305042" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638977594345305042" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638977594345305042" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638977594345305042" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638977594345305042" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638977594345305042" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638977594345305042" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638977594345305042" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638977594345305042" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638977594345305042" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638977594345305042" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638977594345305042" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638977594345305042" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638977594345305042" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638977594345305042" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638977594345305042" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638977594345305042" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638977594345305042" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638977594345305042" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638977594345305042" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638977594345305042" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638977594345305042" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638977594345305042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638977594345305042" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20251103x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20251103.xsd</File>
    <File>plx-20251103_lab.xml</File>
    <File>plx-20251103_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="plx-20251103x8k.htm">plx-20251103x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20251103x8k.htm": {
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20251103",
   "dts": {
    "schema": {
     "local": [
      "plx-20251103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20251103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20251103_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20251103x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20251103x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20251103x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://protalix.com/20251103",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-105594-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-105594-xbrl.zip
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M\B9OS9&3R2M%6PU6>8TEG.[_%YSJ5W"J5Y53NK&$T\/M.,5;]0N?</:.MV6
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MOG[7^$FOPCV-6(#C,$?0T7M?T?]*HB3)R,44W6,KF+-!^!\,U[T<Y/Q-4HP
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M)H&:S#%%N<NI+-/T/1;>JM+<O.N]8QKSTZZ3 )C-38,_7;]O[?\_4$L#!!0
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MD T::A/XD7?LX KU6_HP<$JNDRD]M_F="&33"W/A Q;5;*N/X J[""_((],
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M8-/3"$E4_-Q 4.3^V!W>GCNC@W87@:LS4XPI%"?N![=(-_7T;_\N\_+HJ9C
M7Z/WO(S.9/8))CGU8EK(</G_/.5GEPJ+]H.QUF.L9ZTD5@P.":*X\IL(;Q7:
MN;R\["7,A#WHAQ6QI;[:>7"OOPCW-AY]_U5;2= 2\KI[B_K9H/&:W==W T->
M>]H% \M/[@P7RE%%B'83OXL1CAD5KR[C1QU<OAF")./M$1[@W$532CN'((,M
M]O/14-.9)\%5%OVX!B90,(=U*^  !^4K&DS(!U2AN#VZ:D0%D$+38T25S@,*
MW$X\SABS#SJ'. *@A/]7J&"DQX:R%WZ>KIU6GD@/<U5!-?!4V4ZVWWN?SE"_
M.=GY,#?X6E)A 16$D;\\,S_4B;8^VS&J,]B5C&:1L+$GAOOB$K A83'E9IM*
MV[/<QLC,2OP$P1FN*1]RON;"Z(2_XCXE5"QM=PXDAJ"=]P%\3:D/P-TQY?+=
M=<G"D42[=\UF$!<THO8'VH\OG:>[M>HK25]KE\XSR*ZY%/_PZL[K$U(GC38Q
MQ1KK_E(7YRH]796!NFF5.VMT\TPF:FC,^3?NYK2 Y1E;^3E,NTX_OWY&^VLT
M#R/R;3OXS=3OZN&J+.@W%>T_T3%B7PCS5A^/\SV3B0TE'L,M!?]B)&%D$LX;
M&F^_V_ZC=TCS7%F*3,2]9@ V5B44KRED$^[VD<%04\2E>A2>5K,0/D6*?$!=
M55Q^E$GV4+.L.^3\57B%>HB).PSA"1XXN>J)4X^70.!(6U_8P=0#BXRI'.)]
M[XS*8DW*1#^E&I3C^9+\S6=/C[?"(2T>GLE(+_U.ZZ1%[1)U>(A+G[C.;9G6
MD!<%?OIWK=JW?Z3A_HO3<+1;BU:?TC\^@46B5JA+D:MJ8OS!#T&@_-%!,[%I
M1,4GSG61UH[K][H.TJD(_1?*]F8*90(?( /\+IQWLMZ,0(?UIVZ17#2!I%N(
M,$\ZNQ_4]CBK*0,?#K"X_K2*Y[).*%04@&*GH:N)0GFY]))4$?GU"!Y4;5M2
MU<AS!R(24^@8_V,K/^JL$SRUUEDZ%9]U1.?D!))[R_TZ1=G&V'&GJ7'I<*UD
M<RC3<#I+!T 3-'[;S0>"@;!7DL*E.[M_J7J9VUD58D<*>Q<J;AZ(_OBSF9G1
MXJQ7]HY[#4^%\/BMC$Q3K+2\YNWW2UTJ4H-^NXNK.#S;MC14^L>QAML8+@[0
MX[6QJN:B&@O&,V3(VJ4@;)L8JM.W* =PUE.=DMM]*-Z\_36<UC<8[-$N[I:5
MF1G,-HEO3IY/,ZX?K.D\/:>N%\ZZH$)<:WQE#6#(T5Q?!S?V19%@BG,0Q4]?
M4_NGU_?P^N2=Z[)NY7R[=SR.9I4UW[GF\$\,$S]Q?B)\>\I==E_"=Z)5.:LP
MY;0*7QXE7*>&PY]MIZXJ7] @*\[O>4)\I(>R7L1%X%=?9$D!G\)4'(A+Z#P\
MV@IOB&VAV2FXYK<4SYJA%T9AN)D?KL\DT(U<PI"5M76U]+D_WH0D1T [T@XI
M: BUKANYIKMOK+Z@N-^92F@3!\4:7^+7V"N4MXJWV1\GS,^#@X,]'QX#O,E]
M-<9._XC*EA-=HI4.7QD<Q3M#Z!@HG<7+5-^57_,XQ>=@C!:N0ADL73*^@G[Y
M>IVEBQ=Y7]+2U5Q.%R^1L"]=HUT:M&UKZ0:%?Y:)Q03_?LT8_+D;BU<O=;;4
M[B4]&*_-:O#H/!_GBV.L#U^,A--@8AD34<P ?JP>Z@#4@/+1=)%=6MS$B^F6
M&&J1WUP]I$%1H^>%N?0U/W7A/U,%G0M70K4[<Y%/VLII+!($JH$)&-45!VYG
MD5AZ,Y9#4A1<CT94[@X""-=!(IJCG5M4$:-'XA>(]9X'&</:QG,F!3/BR)/I
MN2R4>DKNE(4LD!9.@\3<L#_$^S7X-,K%/*$N+DQV01%SSDJGBM+(;"ZIIC B
MI1%7,L8!LO\TO_,D;AOP P^:HP@'J8+LW&\\&?ELO&LLS7PK5)V90''$>>=#
M5?W,QZEL>DA4LVL0JB,G:^;-T6%8S&BRXF&=JW#&4?N=Q3T8WN!S@+ZL?$Z4
M7%!5:;^GRBJ=#Z&N5(-IK!I3(2S5Q5QW2$ZHV,%<1OTU-%>$I*3?Y$6* 0SH
M7<\&M$;OE4[*U1>MH^4"WCCR7V*J $MNZS(.= :C=@\ H@SO^F+>26L5IPC]
M4RU$Q@46 ,WQN&-^Q7G52I( A$+S0<ZW8RPE7LB<>%!9"ZV/:UQL&^<Y,_XH
MO%B0+#]*V#:K2Y]$SLE2$W,D$GZ]'A?S+:N/0TI@3%IJ9-8/S>Z%U_?>>M Y
M>G2B7D9:;?6<ST\0'Z$ZFQ5<B9M>VHOI#V=M^FL]M3S'=-01Y-7OQHXI&,J'
M!>B,Z\&GHT*I!7&"2ZO\:4/X/JQ9)A@MPU.DO5FAM*K9]>.QZ^Q,6C&A_5>9
M)Y4T=!P\N9Q4*D+BQ(?1<GU8G+(C7UC9%(_/0B;0V=&(X+7?0]DD:8*"C[]M
M:I,AXUGT"@+O=O@(4S3AER^DB6Z85^+JA9E<!M3MPNYER?6'I%YH../A<-2C
M:V:JI<T6=M'Y"6- $XZK"G-!@^0T7,8U.&2]_"&$M#EK-,+=9'ITO?J!AJJ#
M=G#UJ%UWO^3A .Q/0G4L/M"Y5U@!L@S7:2DNQ_*YS[*.'@L7_^D<\F5*]H\8
M-,W4,.90AGK;^9$?A3W>$Z_#;[**X(Y6:(-W?0%V5(2R_.-E/(\[2%8U+:%>
M/%"<O1EZXQ(G>K)MEVA5O)+U_M4L@[S-!Q<DDX)+:Q77-7E.\(%!';V3FR<+
M]'LFY%1E)B]ITV\=BY(#8[8W4;PO> <&(W(&,"ISBD,61S_"?/_=8;Z9HAD%
M;)+Z;5W>HA$^HX(N C6-SN.(=,L7H39.KCSWM0[6#F<GW,:[@@;0A <SKG.,
M%HR/! $3LAING41-<,^K*-+.!FHA>$*4OB_Y->ZGE43FL!SPC:\^F/K#]:!Z
M A2 C/QP\V_IYJ\JJJ%(HZ3]L!68R?^C#W:MQL_.IPR>I&W>UJO>]B?-:.*+
MA%/ (W66:&;"NH@V^^&V]DVME(237.KL<(W,H^.HMOT'%:2X1!,";U<9B*]Y
M[N7^K3+JW_<LSA9-7R]*=%I<* JNS#'1RF7@E0VC6X..5_I<B5=FJFQ'O(H[
M4YY"(9 67*_7S^'0X_2"=C=ZWKQU3RL?_-]!]_[@07>WO]^]M]N_?ZMW;MWX
MVM*1YS2W43AD&&Z["N=[(HHOA0\71J>?0@_;_A_=W.9_L_,_4$L! A0#%
M  @ @(5C6QRBA1E: P  2PL  !               ( !     '!L>"TR,#(U
M,3$P,RYX<V102P$"% ,4    " " A6-;Z32HW90%  "-/@  %
M    @ &( P  <&QX+3(P,C4Q,3 S7VQA8BYX;6Q02P$"% ,4    " " A6-;
M?FT[IH0$   &*@  %               @ %."0  <&QX+3(P,C4Q,3 S7W!R
M92YX;6Q02P$"% ,4    " " A6-;UKL&T4<5   KFP  $P
M@ $$#@  <&QX+3(P,C4Q,3 S>#AK+FAT;5!+ 0(4 Q0    ( ("%8UM1$G13
M^1D  #-T   7              "  7PC  !P;'@M,C R-3$Q,#-X97@Y.60Q
:+FAT;5!+!08     !0 % $@!  "J/0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>plx-20251103x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20251103.xsd" xlink:type="simple"/>
    <context id="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-11-03</startDate>
            <endDate>2025-11-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_de-KN9oQA0CK6xEAmT-suw_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_Ue2kbsW0GUG90t2I3p1rEQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_ntgS5ZV3m02PzYkrFhbE9w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_yMZLJ3hXNUS_4aEfeHp03Q">2025-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_AIoaWmmyIkq2HIQVRreFSw">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_HoNlW5W6XUOTern_pLxp0w_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_mU-GmT1W5Ea4GOB3j5FWpQ_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_xvgG2koBAU62yP3bf5y_Fw_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_WjxqoVnOlEO9xDhahRMrrA_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_xcznGRV9H0uPPFT2fy9t-Q_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_BrRBU2W5akeJfje23bucDw">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_3nu3YpvD4EqK5JJy-vj86w">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_yGhUkSrnN0OB1jQElg5zyw_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_JitYTEvMZkW1_SN9XRHpMg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_2c1RZRVjgEe-Pw2eXxzsVg">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_yWq3PfyWOkW0I1kS9wwLXg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_Huli07RVo0mEEpcKgXLEOQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_F8uOByrEb0KH7M6IS_fZlA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_XVlNtihHW0mbCtGN7P7SSA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_Coaiyv1vik2yxlwmcjTYrQ_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_vN4mfBnLDkWPhiBknzVT0g_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Tc_4IAXicxuMUCMajibyrunYA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_3_2025_To_11_3_2025_RY6z-WWNU0u2KuzLQ18GOw"
      id="Narr_dJm_ERjlZEu5ngMHiLQkZg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
